MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.
Desai J, Kortmansky J, Segal N, Fakih M, Oh D, Kim K, Rahma O, Ko A, Chung H, Alsina M, Yeh K, Li S, Al-Sakaff N, Patel J, Barak H, Wang J, Zhang X, Bleul C, Cha E, Lee J. MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2019, 37: tps467-tps467. DOI: 10.1200/jco.2019.37.4_suppl.tps467.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaII trialUnacceptable toxicityClinical benefitColorectal cancerSignificant survival benefitGastroesophageal junction cancerCancer immune responseImmune escape mechanismsMultiple tumor typesSingle control armPrimary endpointSecondary endpointsDurable responsesJunction cancerSurvival benefitTreatment armsClinical efficacyGastrointestinal cancerPT cohortCancer immunotherapyControl armDuctal adenocarcinomaImmune responseMinimal efficacy